컴패스 테라퓨틱스(CMPX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.86 (+0.54%), 시가총액 $0.34B, 52주 최저~최고 $1.67 ~ $6.69.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a
컴패스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
컴패스 테라퓨틱스의 현재 주가는 $1.86 (+0.54%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
컴패스 테라퓨틱스의 시가총액은 약 $0.34B입니다.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The comp